What happened to the CSL (ASX:CSL) share price in October?

How did CSL shares perform last month? We take a closer look

| More on:
Scientists working on a screen in laboratory

Image source: Getty Images

The CSL Limited (ASX: CSL) share price kicked up a notch in October, nearing its 52-week high of $320.42. While the global biotech didn’t release any market-sensitive news, investors appeared to be buying the company’s shares.

They gained around 4% during October to end the month at $300.49.

At the time of writing, the CSL share price is $310.93, up 0.03% on the day. This means its shares are around 3% off breaking a new 52-week high and are up around 8% over the last month.

How did CSL fare last month?

During early October, CSL released the commentary around its annual general meeting (AGM).

Almost all of the information had already been divulged in previous market updates such as its full-year results in August. However, it didn’t stop investors pushing up the CSL share price on the day to $292.68, a gain of 1.80%.

The surge came despite the S&P/ASX 200 Index (ASX: XJO) falling 0.26% to 7,280 points on the day.

CSL noted that it sees the current FY22 financial year as a transitional one. The board is confident the company can return to sustainable growth in the next 24 months. It has several major expansion projects underway along with developing its R&D pipeline products.

Nonetheless, there is still a strong demand for its portfolio of therapies and vaccines, which have offset plasma collection headwinds.

Plasma levels for FY21 were down about 20% on the previous year and these were collected at a higher cost per litre. This came from additional PPE and cleaning requirements, social distancing and labour costs as well as higher compensation paid to donors.

Most recently, a couple of brokers rated the company’s shares following CSL’s annual R&D day.

Multinational investment firm Goldman Sachs raised its price target by 1% to $305.00, while Jefferies had a more bullish outlook. The latter lifted its 12-month view by 3.1% to $338.00. Based on the current share price, this implies an upside of around 9% on Jefferies’ assessment.

CSL share price review

When looking over the last 12 months, the CSL share price has gained around 6%. Year-to-date it has fared slightly better, up almost 10% for the period.

CSL presides a market capitalisation of roughly $141.49 billion, and has approximately 455.67 million shares on issue.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »

health workers shake hands and congratulate each other on good news
Healthcare Shares

Here’s why the Atomo (ASX:AT1) share price is rocketing 17% today

Key points Atomo shares accelerate on back of New Zealand approval for its antigen test Businesses and pharmacies allowed to …

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Share Fallers

Polynovo (ASX:PNV) share price melts 31% in 2 weeks. What’s going on?

Key points The Polynovo share price has slipped more than 30% in the past 2 weeks Pressure has been on …

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Can the CSL (ASX:CSL) share price reach pre-COVID highs?

Key Points CSL shares continue to face challenging market conditions Recent placement a factor in share price weakness Brokers put …

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the Telix Pharmaceuticals (ASX:TLX) share price plummeting 13% today?

Key points The Telix Pharmaceuticals share price is down 13% on Monday The company’s December quarterly report revealed a 51% …

Read more »